Acellular pertussis vaccines: A turning point in infant and adolescent vaccination

Infectious Agents and Disease

Volumn 5, Issue 1, 1996, Pages 21-28

  Rappuoli, Rino ^a  

^a CHIRON VACCINES   (Italy)

Author keywords

Acellular; Cellular; Combinations; Immunization; Pertussis; Vaccine; Whooping cough

Indexed keywords

PERTUSSIS VACCINE;

BORDETELLA PERTUSSIS; DRUG DESIGN; DRUG SAFETY; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; REVIEW;

ADOLESCENT; ADULT; BORDETELLA PERTUSSIS; CHILD; CHILD, PRESCHOOL; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; IMMUNIZATION; INFANT; PERTUSSIS VACCINE; SAFETY; VACCINES, SYNTHETIC; WHOOPING COUGH;

EID: 0030053664     PISSN: 10562044     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Ad hoc group for the study of pertussis vaccine: placebocontrolled trial of two acellular pertussis vaccines in Sweden. Protective efficacy and adverse events. Lancet 1988;i:955-60.
2. Addiss DG, Davis JP, Meade BD, Burstyn DG, Meissner M, Zastrow JA, Berg JL, Drinka P, Phillips R. A pertussis outbreak in a Wisconsin nursing home. J Infect Dis 1991;164:704-10.
3. Aricò B, Miller JF, Roy C, Stibitz S, Monak D, Falkow S, Gross R, Rappuoli R. Sequence required for expression of B. pertussis virulence factors share homology with prokaryotic signal tranduction proteins. Proc Natl Acad Sci USA 1989;86:6671-5.
4. Barbieri JT, Cortina G. ADP-ribosyltransferase mutations in the catalytic S-1 subunit of pertussis toxin. Infect Immun 1988 ;56:193-41.
5. Burnette WN, Cieplak W, Mar VL, Kaljot KT, Sato H, Keith JM. Pertussis toxin S1 mutant with reduced enzyme activity and a conserved protective epitope. Science 1988;242:72-4.
6. Decker MD, Edwards KM, Steinhoff MC, Rennels MB, Pichichero ME, Englund JA, Anderson EL, Deloria MA, Reed GF. Comparison of thirteen acellular pertussis vaccines: adverse reactions. Pediatrics 1995;96:557-66.
7. De Magistris MT, Di Tommaso A, Bossù P, Nuti S, Oksemberg J, Judd A, Steinman L, Podda A, Tagliabue A, Rappuoli R. Humoral and cellular immunity in adult volunteers immunized with a genetically inactivated mutant of pertussis toxin. In: Manclark CR, ed. Proceedings 6th International Symposium on Pertussis. Bethesda, September 26-28 1990. Bethesda: FDA, 1990:161-5.
8. Domenighini M, Relman D, Capiau C, Falkow S, Prugnola A, Scarlato V, Rappuoli R. Genetic characterization of Bordetella pertussis filamentous hemagglutinin: a protein processed from an unusually large precursor. Mol Microbiol 1990;4:787-800.
9. Edwards KE, Meade BD, Decker MD, Reed GF, Rennels MB, Steinhoff MC, Anderson EL, Englund JA, Pichichero ME, Deloria MA, Deforest A. Comparison of thirteen acellular pertussis vaccines: overview and serologic response. Pediatrics 1995;96:548-557.
10. Edwards KM. Acellular pertussis vaccines - a solution to the pertussis problem. J Infect Dis 1993;168:15-20.
11. Farizo KM, Cochi SL, Zell ER, Brink EW, Wassilak SG, Patriarca PA. Epidemiological features of pertussis in the United States, 1980-1989. Clin Infect Dis 1992;14:708-19.
12. Fine PE. Can pertussis be eradicated? Tokai J Exp Clin Med 1988;13(suppl):129-31.
13. Glenny AT, Hopkins BE. Diphtheria toxoid as an immunizing agent. Br J Exp Pathol 1923;4:283-8.
14. Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, Anemona A, Ciofi degli Atti ML, Giammanco A, Panci P, Blackwelder WC, Klein DL, Wassilak SGF, Progetto Pertosse Working Group. Clinical efficacy, immunogenicity and safety of two acellular and one whole-cell pertussis vaccines: results from the Italian trial. N Engl J Med (in press).
15. Gustafsson L, Hallander HO, Olin P, Reizenstein BA, Storsaeter J. Marked differences in efficacy, immunogenicity and reactogenicity between a 5-component acellular, a 2-component acellular, and a U.S. licensed whole-cell pertussis vaccine in a placebo-controlled efficacy trial in Sweden. N Engl J Med (in press).
16. He QS, Viljanen MK, Nikkari S, Lyytikainen R, Mertsola J. Outcomes of Bordetella pertussis infection in different age groups of an immunized population. J Infect Dis 1994;170:873-7.
17. Herwaldt LA. Pertussis in adults. What physicians need to know. Arch Intern Med 1991;151:1510-12.
18. Herwaldt LA. Pertussis and pertussis vaccines in adults [Editorial; comment]. JAMA 1993;269:93-4.
19. Howson CP, Fineberg HV. Adverse events following pertussis and rubella vaccines. Summary of a report of the Institute of Medicine. JAMA 1992;267:392-6.
20. Jenkinson D. Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study. Br Med J 1988;296:612-14.
21. Kosecka U, Marshall JS, Crowe SE, Bienenstock J, Perdue MH. Pertussis toxin stimulates hypersensitivity and enhances nerve-mediated antigen uptake in rat intestine. Am J Physiol 1994;30:G745-53.
22. Lacey BW. Antigenic modulation of Bordetella pertussis. J Hyg 1960;58:57-93.
23. Locht C, Keith JM. Pertussis toxin gene: nucleotide sequence and genetic organization. Science 1986;232:1258-64.
24. Locht C, Lobet Y, Feron C, Cieplak W, Keith JM. The role of cysteine 41 in the enzymatic activities of the pertussis toxin S1 subunit as investigated by site-directed mutagenesis. J Biol Chem 1990;265:4552-9.
25. Miller E, Waight P, Ashworth E, Thornton C, Redhead K. Summary of clinical and laboratory data for acellular and whole cell pertussis vaccines from UK studies. In: Salisbury M, ed. Compatibility of acellular pertussis with other vaccines in UK primary immunization and boosting schedules. London: PHLS, CAMR and NIBSC, 1995:1-16.
26. Miller JF, Mekalanos JJ, Falkow S. Coordinate regulation and sensory transduction in the control of bacterial virulence. Science 1989;243:916-22.
27. Mink CM, Cherry JD, Christenson P, Lewis K, Pineda E, Shlian D, Dawson JA, Blumberg DA. A search for Bordetella pertussis infection in university students. Clin Infect Dis 1992;14:464-71.
28. Mink CM, Sirota NM, Nugent S. Outbreak of pertussis in a fully immunized adolescent and adult population. Arch Pediatr Adolesc Med 1994;148:153-7.
29. Moxon ER, Rappuoli R. Haemophilus influenzae infections and whooping cough. Lancet 1990;335:1324-9.
30. Muller AS, Leeuwenburg J, Pratt DS. Pertussis: epidemiology and control. Bull WHO 1986;64:321-31.
31. Munoz JJ, Peacock MG, Hadlow WJ. Anaphylaxis or so-called encephalopathy in mice sensitized to an antigen with the aid of pertussigen (pertussis toxin). Infect Immun 1987;55:1004-8.
32. Nencioni L, Pizza M, Bugnoli M, De Magistris T, Di Tommaso A, Giovannoni F, Manetti R, Marsili I, Matteucci G, Nucci D, Olivieri R, Piled P, Presentini R, Villa L, Kreeftenberg H, Silvestri S, Tagliabue A, Rappuoli R. Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough. Infect Immun 1990;58:1308-15.
33. Nicosia A, Perugini M, Franzini C, Casagli MC, Borri MG, Antoni G, Almoni M, Neri P, Ratti G, Rappuoli R. Cloning and sequencing of the pertussis toxin genes: operon structure and gene duplication. Proc Natl Acad Sci USA 1986;83:4631-5.
34. Olin P. Comparing the efficacy of pertussis vaccines [Letter]. Lancet 1989;1:95-6.
35. Pizza M, Bartoloni A, Prugnola A, Silvestri S, Rappuoli R. Subunit S1 of pertussis toxin: mapping of the regions essential for ADP-ribosyltransferase activity. Proc Natl Acad Sci USA 1988;85:7521-5.
36. Pizza M, Covacci A, Bartoloni A, Perugini M, Nencioni L, de Magistris MT, Villa L, Nucci D, Manetti R, Bugnoli M, Giovannoni F, Olivieri R, Barbieri JT, Sato H, Rappuoli R. Mutants of pertussis toxin suitable for vaccine development. Science 1989;246:497-500.
37. Podda A, Deluca EC, Contu B, Furlan R, Maida A, Moiraghi A, Stramare D, Titone L, Uxa F, Dipisa F, Peppoloni S, Nencioni L, Rappuoli R, Bartalini M, Bona G, Budroni M, Pistilli AMC, Cascio A, Cascio G, Cossu M, Dallorto P, Dileo G, Furlan A, Macagno F, Marsili I, Meloni T, Regoli D, Rigo G, Trappan A, Vargiu G, Volpini G. Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine. J Pediatr 1994;124:921-6.
38. Podda A, Deluca EC, Titone L, Casadei AM, Cascio A, Bartalini M, Volpini G, Peppoloni S, Marsili I, Nencioni L, Rappuoli R. Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children. J Pediatr 1993;123:81-4.
39. Podda A, Nencioni L, de Magistris MT, Di Tommaso A, Bossù P, Nuti S, Pileri P, Peppoloni S, Bugnoli M, Ruggiero P, Marsili I, D'Errico A, Tagliabue A, Rappuoli R. Metabolic, humoral, and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9K/129G. J Exp Med 1990;172:861-8.
40. Podda A, Nencioni L, Marsili I, Peppoloni S, Volpini G, Donati D, Di Tommaso A, de Magistris MT, Rappuoli R. Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa. Vaccine 1991;9:741-5.
41. Ramon G. Sur la toxine et sur l'anatoxine diphtheriques. Ann Inst Pasteur 1924;38:1-10.
42. Rappuoli R. Pathogenicity mechanisms of Bordetella. In: Dangl JL, ed. Bacterial pathogenesis of plants and animals. Vol 1. Berlin: Springer-Verlag, 1994:319-36.
43. Rappuoli R, Aricò B, Scarlato V. Thermoregulation and reversible differentiation in Bordetella: a model for pathogenic bacteria. Mol Microbiol 1992;6:2209-11.
44. Sato Y, Kimura M, Fukumi H. Development of a pertussis component vaccine in Japan. Lancet 1984;i:122-6.
45. Steinman L, Weiss A, Adelman N, Lim M, Zuniga R, Ochlert J, Hewlett E, Falkow S. Pertussis toxin is required for pertussis vaccine encephalopathy. Proc Natl Acad Sci USA 1985;82:8733-6.
46. Storsaeter J, Hallander H, Farrington CP, Olin P, Mollby R, Miller E. Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish Phase III trial. Vaccine 1990;8:457-61.
47. Sutter RW, Cochi SL. Pertussis hospitalizations and mortality in the United States, 1985-1988. Evaluation of the completeness of national reporting. JAMA 1992;267(3):386-91.
48. Trollfors B. Bordetella pertussis whole cell vaccines: efficacy and toxicity. Acta Paediatr Scand 1984;73:417-25.
49. Weiss AA, Hewlett EL. Virulence factors of Bordetella pertussis. Annu Rev Microbiol 1986;40:661-86.
50. Wilhelm J, Kenyon T, Mihalek E, Brusealas K, Shulman S, Bergman E, Daum R, Francis BJ, Robinson D, Adcock M, Daniels J, Wells V, Christie C, Reising S, Halpin TJ, Finger R. Resurgence of pertussis - United States. JAMA 1994;271:340.
51. Wright SW, Edwards KM, Decker MD, Zeldin MH. Pertussis infection in adults with persistent cough. JAMA 1995;273:1044-6.